Biopharmas raising money in public or private financings, including: 89bio, Aditx, Biophytis, Can-Fite, Castle, Inozyme, Nkarta, Nurix, Paxmedica, Pfizer, Poseida, Sun, Unum, Vir.

Biopharmas raising money in public or private financings, including: Aeterna Zentaris, Annexon, CF Pharmtech, Derm-Biome, Mimedx, Neoleukin.

Biopharmas raising money in public or private financings, including: Acceleron, Akari, Akouos, Amylyx, Chiasma, Crispr Therapeutics, DFP Healthcare Acquisitions, IMV, Orphazyme, Painreform, Panacea Acquisition, Tela Bio.

DUBLIN – Gene therapy developer Freeline Therapeutics Ltd. added $80 million in new investment to take its series C round to $120 million in total. The new cash will help to fund a pivotal trial of its lead gene therapy program in hemophilia B, enable it to continue a phase I/II trial of a gene therapy in Fabry disease and allow it to progress its preclinical programs in Gaucher disease and hemophilia A, while also making ongoing investments in its adeno-associated virus (AAV) gene therapy technology and its manufacturing platform.

Biopharmas raising money in public or private financings, including: Acceleron, Aditx, Antibe, Arch Biopartners, Cel-Sci, Cohbar, Crispr, Evecxia, Goldfinch, Iterum, Magenta, Nantkwest, Oncology Venture, Pharmenable, Predictive Oncology, Redx, TLC, Vaxil.

PERTH, Australia – Melbourne-based Neuren Pharmaceuticals Ltd. will be able to progress NNZ-2591 to the clinic for three orphan indications after raising AU$20 million (US$13.75 million) in a placement to institutional and sophisticated investors in Australia, New Zealand, Hong Kong and the U.K.

Biopharmas raising money in public or private financings, including: Achieve, Alx Oncology, Berkeley Lights, Biontech, Biosig, Editas, Geovax, Kiromic, Pandion, Soleno, Therapix.